aTyr Pharma, Inc. shares had a trading volume of 26K in the last trading session. Overall, volume was down 82.58% under the stocks normal daily volume.
Short traders are feeling a little more bullish on shares of the company lately as evidenced by the change in short interest. The stock had a fall in short interest of -6.32% as of October 13, 2017 from the last reporting period. Short interest fell from 315,306 to 295,383 over that timeframe. With short interest at 295,383 and short average daily volume at 172,609, the short-interest ratio is 2.0 and the short interest percentage is 0.01% as of October 13.
aTyr Pharma, Inc. (NASDAQ:LIFE) has been the object of insider buying activity recently. CEO John Mendlein purchased 37,736 shares at an average price of $2.65 on Thu the 31st. That brings the CEO’s holdings to $974,890 as reported to the SEC. Director Paul Schimmel disclosed the purchase of 94,336 shares of LIFE stock. The shares were bought on August 31st for an average price of $2.65. The Director now owns $1,001,480 of the stock according to the SEC filing.
Here are a few substantial investment firms who have updated their positions. As of quarter end Goldman Sachs Group Inc had sold 9,931 shares trimming its position 31.0%. The value of the investment in LIFE decreased from $112,000 to $75,000 a change of $37,000 since the last quarter. Renaissance Technologies LLC augmented its ownership by buying 21,500 shares an increase of 55.4% as of 06/30/2017. Renaissance Technologies LLC claims 60,300 shares valued at $205,000. The total value of its holdings increased 50.7%.
Blackrock Inc. downsized its investment by shedding 13,588 shares a decrease of 82.3% from 03/31/2017 to 06/30/2017. Blackrock Inc. owns 2,926 shares with a value of $10,000. The value of the position overall is down by 82.8%. Alyeska Investment Group, L.p. added to its stake by buying 29,622 shares an increase of 3.7%. Alyeska Investment Group, L.p. now controls 839,264 shares worth $2,853,000. The value of the position overall is up by 0.7%.
The company is down from yesterday’s close of $4.80. The stock last traded at $4.80 just above the 50 day moving average of $4.79 and a tad above the 200 day moving average of $4.74. The 50 day moving average was up $0.01 and the 200 day average was up $0.06.
As of the last earnings report the EPS was $-2.19 and is projected to be $-2.18 for the current year with 23,839,000 shares now outstanding. Analysts expect next quarter’s EPS to be $-0.46 and the next full year EPS is anticipated to be $-1.82.
aTyr Pharma, Inc., launched on October 8, 2005, is a clinical-stage biotherapeutics company. The Company is involved in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B..